Lee and colleagues identify MFT251 as a synthetic small-molecule TBK1 agonist that directly activates type I interferon signaling. MFT251 induces broad antiviral defenses and reshapes the tumor microenvironment to enhance antitumor immunity, establishing pharmacologic TBK1 activation as a strategy for innate immune modulation in infection and cancer.